Lulitreat 1% Cream contains Luliconazole 1% w/w, a topical antifungal agent belonging to the imidazole class, indicated for the treatment of superficial fungal infections of the skin. Luliconazole exhibits broad-spectrum antifungal activity against dermatophytes, yeasts, and molds by inhibiting the synthesis of ergosterol, an essential component of fungal cell membranes, thereby disrupting cell membrane integrity and leading to fungal cell death. Lulitreat 1% Cream is primarily prescribed for conditions such as tinea corporis, tinea cruris, and tinea pedis. The cream formulation allows for effective penetration into the stratum corneum, ensuring targeted antifungal action with minimal systemic absorption. It is applied topically once daily to the affected area and surrounding skin, typically for a duration of 2 to 4 weeks depending on the clinical response and severity of infection. Common adverse effects are generally mild and may include localized irritation, burning sensation, or erythema at the application site. Lulitreat 1% Cream should be used with caution in patients with known hypersensitivity to luliconazole or other imidazole derivatives. It is contraindicated in individuals with open wounds or severe skin conditions in the area of application. Proper adherence to prescribed treatment duration is essential to prevent recurrence and resistance.